Lensar (LNSR) Long-Term Investments (2023 - 2024)

Lensar (LNSR) reported Long-Term Investments of $494000.0 for Q3 2024, down 59.97% quarter-over-quarter from $1.2 million in Q2 2024.

Lensar (LNSR) Long-Term Investments (2023 - 2024) Analysis & Trends

Lensar (LNSR) has 2 years of Long-Term Investments data on file, last reported at $494000.0 in Q3 2024.

Long-Term Investments for Q3 2024 came in at $494000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $494000.0 (changed N/A YoY), and the FY2023 annual result was $492000.0, changed N/A from the prior year.
Long-Term Investments fell to $494000.0 in Q3 2024 per LNSR's latest filing, from $1.2 million in the prior quarter.
Over five years, Long-Term Investments peaked at $1.2 million in Q1 2024 and troughed at $492000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	1.09 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	-
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	-
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	-
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	285.60 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	166.25 Mn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	-
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	-
10	Lensar	70.05 Mn	70.34 Mn	6.38 Mn	-

Download Data